Fate Therapeutics, Inc.
FATE
$1.12
$0.010.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.47M | 13.34M | 13.63M | 13.45M | 12.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.47M | 13.34M | 13.63M | 13.45M | 12.32M |
| Cost of Revenue | 84.75M | 86.16M | 89.16M | 88.43M | 88.06M |
| Gross Profit | -76.28M | -72.83M | -75.53M | -74.99M | -75.74M |
| SG&A Expenses | 77.75M | 83.56M | 90.64M | 92.25M | 90.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 186.11M | 199.09M | 209.17M | 210.05M | 207.82M |
| Operating Income | -177.64M | -185.75M | -195.54M | -196.60M | -195.51M |
| Income Before Tax | -171.52M | -175.88M | -186.26M | -178.23M | -175.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -171.52 | -175.88 | -186.26 | -178.23 | -175.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -171.52M | -175.88M | -186.26M | -178.23M | -175.72M |
| EBIT | -177.64M | -185.75M | -195.54M | -196.60M | -195.51M |
| EBITDA | -161.61M | -168.28M | -176.58M | -177.57M | -176.34M |
| EPS Basic | -1.45 | -1.49 | -1.65 | -1.65 | -1.71 |
| Normalized Basic EPS | -0.83 | -0.85 | -0.95 | -1.07 | -1.10 |
| EPS Diluted | -1.45 | -1.49 | -1.65 | -1.65 | -1.71 |
| Normalized Diluted EPS | -0.83 | -0.85 | -0.95 | -1.07 | -1.10 |
| Average Basic Shares Outstanding | 472.47M | 471.41M | 454.14M | 434.96M | 415.75M |
| Average Diluted Shares Outstanding | 472.47M | 471.41M | 454.14M | 434.96M | 415.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |